This usually takes about 10 seconds
Class safety (regulatory labeling): the boxed warning and monitoring guidance are extrapolated from the broader FDA/EMA GLP-1 class labeling, not yet from a Retatrutide-specific approved label (there isnt one)
Potts JE, Gray LJ, Brady EM, et al
Nissen expects tirzepatide to soon join the pure GLP-1 RAs with an FDA-approved indication for weight loss in addition to diabetes, although it may meet the same payer reluctance around reimbursement for weight loss that the pure GLP-1 RAs have
Label and Store: If it's not already dated, label your vial with the date of reconstitution and the final concentration (e.g., 'Retatrutide 5mg/mL 10/26/23')
( B ) Representative photomicrographs of TTC-stained heart sections show infarcted (white) versus viable (red) tissue on day 4 after MI